Prostate Cancer CTC PSMA Status Could Guide Therapy
PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
Recent findings suggest it may be possible to spare patients unnecessary exposure to radiation.
Persistent PSA after salvage radical prostatectomy is linked to an increased risk of adverse outcomes in patients with prostate cancer.
Dabrafenib plus trametinib improved the overall response rate and prolonged progression-free survival, compared with standard chemotherapy.
A subset of patients treated with temozolomide plus veliparib may have extended survival following retreatment with temozolomide at first recurrence.
Transplant after a 3-drug induction regimen can prolong progression-free survival, compared with triplet induction alone, in patients with multiple myeloma.
Adding isatuximab to carfilzomib and dexamethasone significantly improved progression-free survival at a median follow-up of 44 months.
More than 80% of Black survey respondents said they were somewhat or very likely to consider enrolling in a clinical trial.
A 10% increase in public welfare spending was associated with an 8.6% improvement in 5-year overall survival for Black patients with cancer.
Hispanic children had inferior overall survival despite receiving the same treatment as their peers.